Our study demonstrates that the LIPG inhibitor, GSK264220A, is able to reverse the activity of LIPG on HDL; therefore, we propose that anti-lipid metabolism drugs may represent a promising therapeutic strategy for the treatment for CRC in the future. Here, LIPG is linked to colorectal carcinoma.